Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Alpelisib + WEHI-539|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Alpelisib||Piqray||BYL719||PIK3CA inhibitor 18||Piqray (alpelisib) is a selective PIK3CA inhibitor that blocks activation of the PI3K signaling pathway and inhibits tumor growth (PMID: 23726034). Piqray (Alpelisib) is FDA approved in combination with fulvestrant for use in postmenopausal women, and men, with advanced or metastatic hormone receptor (HR)-positive, ERBB2 (HER2)-negative, PIK3CA-mutant breast cancer (FDA.gov).|
|WEHI-539||BCL-XL inhibitor 13||WEHI-539 is a selective inhibitor of BCL-XL that stimulates apoptotic responses in cells, resulting in killing of tumor cells (PMID: 23603658, PMID: 32752193).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|PIK3CA act mut||breast cancer||no benefit||Alpelisib + WEHI-539||Preclinical - Cell culture||Actionable||In a preclinical study, Alpelisib (BYL719) did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663).||27974663|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|